In 1952 the two researchers Ernst Brandl and Hans Margreiter from Kundl discovered the acid-stable penicillin V. The life-saving antibiotic could now also be administered in tablet form. It is still on the market today.
Since the 1970s, (semi-)synthetic and broad-spectrum antibiotics such as AmoxC have also been produced in Kundl. Hardly any other European site has so much experience and know-how in the development and production of anti-infectives.
Today more than 60% of the world production of penicillin is supplied out of Kundl. The site is part of the global Novartis Group, one of the world’s largest antibiotics producers and the last fully integrated penicillin producer in the western world.
Until 2025 Novartis and the Austrian Federal Government will invest a total of 150 million Euro to keep the production of the life-saving penicillin in Tyrol (and thus in Europe).
A global competence centre for microparticle technology was opened in 2014. In 2015, the state-of-the-art biologicals production facility for ready-to-use syringes and auto-injectors, BioInject, went into operation. In 2017, the cell culture production was expanded and a new office building was inaugurated. This led to the creation of 190 additional jobs.
Be part of this success story!